Peptides derived from a distinct region of GB virus c glycoprotein E2 mediate strain-specific HIV-1 entry inhibition

Journal of Virology

Volumn 85, Issue 14, 2011, Pages 7037-7047

  Koedel, Yvonne ^a   Eissmann, Kristin ^a   Wend, Holger ^a   Fleckenstein, Bernhard ^a   Reil, Heide ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN E2; GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 41; VIRUS ENVELOPE PROTEIN;

AMINO TERMINAL SEQUENCE; ARTICLE; CLADISTICS; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; HEPATITIS G VIRUS; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IN VITRO STUDY; NUCLEOTIDE SEQUENCE; PEPTIDE ANALYSIS; PRIORITY JOURNAL; PROTEIN INTERACTION; SENSITIVITY ANALYSIS; VIRION; VIRUS ATTACHMENT; VIRUS ENTRY; VIRUS INHIBITION; VIRUS INTERFERENCE; VIRUS PARTICLE; VIRUS REPLICATION; VIRUS STRAIN;

AMINO ACID SEQUENCE; CELLS, CULTURED; GB VIRUS C; HIV-1; HUMANS; MEMBRANE FUSION; MOLECULAR SEQUENCE DATA; PEPTIDES; VIRAL ENVELOPE PROTEINS;

FLAVIVIRIDAE; GB VIRUS C; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 79960384755     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.02366-10     Document Type: Article

References (40)

1. Alter, H. J. 1997. G-pers creepers, where'd you get those papers? A reassessment of the literature on the hepatitis G virus. Transfusion 37:569-572.
2. Arthos, J., et al. 2002. Biochemical and biological characterization of a dodecameric CD4-Ig fusion protein: implications for therapeutic and vaccine strategies. J. Biol. Chem. 277:11456-11464.
3. Birk, M., S. Lindback, and C. Lidman. 2002. No influence of GB virus C replication on the prognosis in a cohort of HIV-1-infected patients. AIDS 16:2482-2485.
4. Bjorkman, P., et al. 2004. GB virus C during the natural course of HIV-1 infection: viremia at diagnosis does not predict mortality. AIDS 18:877-886.
5. Cantin, R., S. Methot, and M. J. Tremblay. 2005. Plunder and stowaways: incorporation of cellular proteins by enveloped viruses. J. Virol. 79:6577-6587.
6. Cavrois, M., C. de Noronha, and W. C. Greene. 2002. A sensitive and specific enzyme-based assay detecting HIV-1 virion fusion in primary T lymphocytes. Nat. Biotechnol. 20:1151-1154.
7. Derdeyn, C. A., et al. 2000. Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120. J. Virol. 74:8358-8367.
8. Feucht, H. H., et al. 1997. Prevalence of hepatitis G viremia among healthy subjects, individuals with liver disease, and persons at risk for parenteral transmission. J. Clin. Microbiol. 35:767-768.
9. George, S. L., J. Xiang, and J. T. Stapleton. 2003. Clinical isolates of GB virus type C vary in their ability to persist and replicate in peripheral blood mononuclear cell cultures. Virology 316:191-201.
10. Herrera, E., M. J. Gomara, S. Mazzini, E. Ragg, and I. Haro. 2009. Synthetic peptides of hepatitis G virus (GBV-C/HGV) in the selection of putative peptide inhibitors of the HIV-1 fusion peptide. J. Phys. Chem. B 113:7383-7391.
11. Herrera, E., et al. 2010. Effect of synthetic peptides belonging to E2 envelope protein of GB virus C on human immunodeficiency virus type 1 infection. J. Med. Chem. 53:6054-6063.
12. Hsu, M., et al. 2003. Increased mucosal transmission but not enhanced pathogenicity of the CCR5-tropic, simian AIDS-inducing simian/human immunodeficiency virus SHIV(SF162P3) maps to envelope gp120. J. Virol. 77:989-998.
13. Jung, S., et al. 2007. HIV entry inhibition by the envelope 2 glycoprotein of GB virus C. AIDS 21:645-647.
14. Jung, S., et al. 2005. Inhibition of HIV strains by GB virus C in cell culture can be mediated by CD4 and CD8 T-lymphocyte derived soluble factors. AIDS 19:1267-1272.
15. Kramer, H. B., et al. 2010. Elevation of intact and proteolytic fragments of acute phase proteins constitutes the earliest systemic antiviral response in HIV-1 infection. PLoS Pathog. 6:e1000893.
16. Larios, C., et al. 2005. Characterization of a putative fusogenic sequence in the E2 hepatitis G virus protein. Arch. Biochem. Biophys. 442:149-159.
17. Lefrere, J. J., et al. 1999. Prevalence of GB virus type C/hepatitis G virus RNA and of anti-E2 in individuals at high or low risk for blood-borne or sexually transmitted viruses: evidence of sexual and parenteral transmission. Transfusion 39:83-94.
18. Lefrere, J. J., et al. 1999. Carriage of GB virus C/hepatitis G virus RNA is associated with a slower immunologic, virologic, and clinical progression of human immunodeficiency virus disease in coinfected persons. J. Infect. Dis. 179:783-789.
19. Marzi, A., et al. 2007. Modulation of HIV and SIV neutralization sensitivity by DC-SIGN and mannose-binding lectin. Virology 368:322-330.
20. Mazzini, S., et al. 2007. 3D-Structure of the interior fusion peptide of HGV/GBV-C by 1H NMR, CD, and molecular dynamics studies. Arch. Biochem. Biophys. 465:187-196.
21. Munch, J., et al. 2007. Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide. Cell 129:263-275.
22. Nattermann, J., et al. 2003. Regulation of CC chemokine receptor 5 in hepatitis G virus infection. AIDS 17:1457-1462.
23. Ott, D. E. 2008. Cellular proteins detected in HIV-1. Rev. Med. Virol. 18:159-175.
24. Reeves, J. D., et al. 2002. Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics. Proc. Natl. Acad. Sci. U. S. A. 99:16249-16254.
25. Schon, A., et al. 2006. Thermodynamics of binding of a low-molecular-weight CD4 mimetic to HIV-1 gp120. Biochemistry 45:10973-10980.
26. Schroter, M., H. H. Feucht, P. Schafer, B. Zollner, and R. Laufs. 1999. GB virus C/hepatitis G virus infection in hemodialysis patients: determination of seroprevalence by a four-antigen recombinant immunoblot assay. J. Med. Virol. 57:230-234.
27. Simons, J. N., et al. 1995. Isolation of novel virus-like sequences associated with human hepatitis. Nat. Med. 1:564-569.
28. Stapleton, J. T., C. F. Williams, and J. Xiang. 2004. GB virus type C: a beneficial infection? J. Clin. Microbiol. 42:3915-3919.
29. Tillmann, H. L., et al. 2001. Infection with GB virus C and reduced mortality among HIV-infected patients. N. Engl. J. Med. 345:715-724.
30. Tilton, J. C., and R. W. Doms. 2010. Entry inhibitors in the treatment of HIV-1 infection. Antivir. Res. 85:91-100.
31. Toyoda, H., Y. Fukuda, T. Hayakawa, J. Takamatsu, and H. Saito. 1998. Effect of GB virus C/hepatitis G virus coinfection on the course of HIV infection in hemophilia patients in Japan. J. Acquir. Immune. Defic. Syndr. Hum. Retrovirol. 17:209-213.
32. Van der Bij, A. K., et al. 2005. GB virus C coinfection and HIV-1 disease progression: the Amsterdam Cohort Study. J. Infect. Dis. 191:678-685.
33. Williams, C. F., et al. 2004. Persistent GB virus C infection and survival in HIV-infected men. N. Engl. J. Med. 350:981-990.
34. +, and SDF-1. Lancet 363: 2040-2046.
35. + Jurkat T cells 2. Proc. Natl. Acad. Sci. U. S. A. 103:15570-15575.
36. Xiang, J., et al. 2001. Effect of coinfection with GB virus C on survival among patients with HIV infection. N. Engl. J. Med. 345:707-714.
37. Xiang, J., S. Wunschmann, W. Schmidt, J. Shao, and J. T. Stapleton. 2000. Full-length GB virus C (hepatitis G virus) RNA transcripts are infectious in primary CD4-positive T cells. J. Virol. 74:9125-9133.
38. Xiang, J. H., J. H. McLinden, Q. Chang, E. L. Jordan, and J. T. Stapleton. 2008. Characterization of a peptide domain within the GB virus C NS5A phosphoprotein that inhibits HIV replication. PLoS One 3:e2580.
39. Yeo, A. E., et al. 2000. Effect of hepatitis G virus infection on progression of HIV infection in patients with hemophilia. Ann. Intern. Med. 132:959-963.
40. Yeo, A. E., A. Matsumoto, J. W. Shih, H. J. Alter, and J. J. Goedert. 2000. Prevalence of hepatitis G virus in patients with hemophilia and their steady female sexual partners. Sex. Transm. Dis. 27:178-182